Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata

Trial Profile

A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs ATI 502 (Primary)
  • Indications Alopecia areata
  • Focus Therapeutic Use
  • Sponsors Aclaris Therapeutics
  • Most Recent Events

    • 17 Dec 2018 According to an Aclaris Therapeutics media release, top-line data from this trial is expected in the second quarter of 2019.
    • 06 Nov 2018 Status changed from recruiting to active, no longer recruiting, according to an Aclaris Therapeutics media release.
    • 03 Aug 2018 According to an Aclaris Therapeutics media release, data from this trial is expected in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top